Date and Time: 6-7 p.m. Thursday, January 31, 2019
Please note that this document is not a direct transcript of the Q&A session from the conference call, but is a simple summary including additions and corrections at the discretion of the company. The results and forecasts are forward-looking statements determined by the Company based on currently available information that may include risks and uncertainties. Please be aware that actual results may vary significantly due to various factors.
Comparing the cumulative nine months of FY2017 and the cumulative nine months of FY2018,
-Price reduction offset by streamlining | -7 billion yen |
-Sales volume and products mix (including royalties) | -14 billion yen |
-Impact of foreign exchange | -2 billion yen |
-Impact of fixed costs | -8 billion yen |
-Others | +6 billion yen |
This all combined to give a loss of 25 billion yen.
Part of the support fee in the technical partnership contract with the Hangzhou Jinjiang Group was recorded in Q3 FY2018.
Sales in Q4 is expected to decrease because of seasonal factors including reduction in operating days during the Chinese New Year.
FY2019 is expected to be a year of accumulating small themes and improvements for strengthening profitability in the future. We will also seek to further improve productivity, taking the opportunity of rebuilding bases to move forward with production location optimization, etc.
Phase 2 study of the RNAi-based investigational drug for idiopathic pulmonary fibrosis (IPF) is expected to be completed in FY2020.
Regarding the investigational new drug application for KRAS mutant tumors, we are preparing to initiate the Phase 1 study.
For any inquiries about Investor Relations.
Business Hours(India time)
08:30-17:00(Except for Second Sat of each month, Sun, and Holidays)
©NITTO DENKO CORPORATION. 2019 All rights reserved.